Findings

What do systematic reviews say?

35 questions · 36 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 22.2%GRADE not reported 4 · 11.1%Very low 12 · 33.3%Low 9 · 25%Moderate 3 · 8.3%High 0 · 0%

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs levonorgestrel intrauterine system

Thromboembolic events · heavy menstrual bleeding

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs no treatment or placebo

Adverse events (any) · women with heavy menstrual bleeding

Antifibrinolytics showed no clear difference in adverse events (any) compared with no treatment or placebo (low certainty).

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
RR 1.05 [0.93, 1.18]
1 study · 297 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs no treatment or placebo

Thromboembolic events · women with heavy menstrual bleeding

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2

Menstrual blood loss: mean loss · women with heavy menstrual bleeding

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 312 participants
Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2

Menstrual blood loss: improvement rates · women with heavy menstrual bleeding

Antifibrinolytics may leads to higher menstrual blood loss: improvement rates (overall) compared with progestogens (low certainty).

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
RR 1.54 [1.31, 1.8]
5 studies · 422 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2

Adverse events (any) · women with heavy menstrual bleeding

Antifibrinolytics may leads to lower adverse events (any) compared with progestogens (low certainty).

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
RR 0.66 [0.46, 0.94]
4 studies · 349 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2

Thromboembolic events · women with heavy menstrual bleeding

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs NSAIDs

Menstrual blood loss: mean loss · women with heavy menstrual bleeding

1 finding from 1 review

Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Number of participants with any bleeding · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Thromboembolism · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 68 participants
Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Mortality (all‐cause) ‐ not reported · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Adverse events associated with transfusion · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Adverse events of antifibrinolytic agents · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 74 participants
Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs placebo

Quality of life ‐ not reported · People with a haematological disorder

1 finding from 1 review

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported